AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (1.5 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Open Access

Role of Receptor Interacting Protein (RIP) kinases in cancer

Kaylee Erminea,b, Jian Yub,c, Lin Zhanga,b( )
Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Show Author Information

Abstract

The Receptor Interacting Protein (RIP) kinase family consists of seven Serine/Threonine kinases, which plays a key signaling role in cell survival and cell death. Each RIP family member contains a conserved kinase domain and other domains that determine the specific kinase function through protein–protein interactions. RIP1 and RIP3 are best known for their critical roles in necroptosis, programmed necrosis and a non-apoptotic inflammatory cell death process. Dysregulation of RIP kinases contributes to a variety of pathogenic conditions such as inflammatory diseases, neurological diseases, and cancer. In cancer cells, alterations of RIP kinases at genetic, epigenetic and expression levels are frequently found, and suggested to promote tumor progression and metastasis, escape of antitumor immune response, and therapeutic resistance. However, RIP kinases can be either pro-tumor or anti-tumor depending on specific tumor types and cellular contexts. Therapeutic agents for targeting RIP kinases have been tested in clinical trials mainly for inflammatory diseases. Deregulated expression of these kinases in different types of cancer suggests that they represent attractive therapeutic targets. The focus of this review is to outline the role of RIP kinases in cancer, highlighting potential opportunities to manipulate these proteins in cancer treatment.

Keywords

Immune responseCancerNecroptosisCell deathRIP kinases

References

1

Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. 1995;81(4): 513-523.
Crossref Google Scholar
2

Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1(6): 489-495.
Crossref Google Scholar
3

Cho YS, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137(6): 1112-1123.
Crossref Google Scholar
4

He S, Wang L, Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009;137(6): 1100-1111.
Crossref Google Scholar
5

Zhang DW, Shao J, Lin J, et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science. 2009;325(5938): 332-336.
Crossref Google Scholar
6

Thome M, Hofmann K, Burns K, et al. Identification of CARDIAK, a RIP-like kinase that associates with caspase-1. Curr Biol. 1998;8(15): 885-888.
Crossref Google Scholar
7

Zhang D, Lin J, Han J. Receptor-interacting protein (RIP) kinase family. Cell Mol Immunol. 2010;7(4): 243-249.
Crossref Google Scholar
8

Meylan E, Tschopp J. The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci. 2005;30(3): 151-159.
Crossref Google Scholar
9

Zha J, Zhou Q, Xu LG, et al. RIP5 is a RIP-homologous inducer of cell death. Biochem Biophys Res Commun. 2004;319(2): 298-303.
Crossref Google Scholar
10

Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat. 2004;23(6): 540-545.
Crossref Google Scholar
11

Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity. 1996;4(4): 387-396.
Crossref Google Scholar
12

Ting AT, Pimentel-Muiños FX, Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J. 1996;15(22): 6189-6196.
Crossref Google Scholar
13

Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity. 1998;8(3): 297-303.
Crossref Google Scholar
14

Cuny GD, Degterev A. RIPK protein kinase family: atypical lives of typical kinases. Semin Cell Dev Biol. 2021;109: 96-105.
Crossref Google Scholar
15

Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4(5): 313-321.
Crossref Google Scholar
16

Liu Y, Fan C, Zhang Y, et al. RIP1 kinase activity-dependent roles in embryonic development of Fadd-deficient mice. Cell Death Differ. 2017;24(8): 1459-1469.
Crossref Google Scholar
17

Xie T, Peng W, Liu Y, et al. Structural basis of RIP1 inhibition by necrostatins. Structure. 2013;21(3): 493-499.
Crossref Google Scholar
18

Rebsamen M, Heinz LX, Meylan E, et al. DAI/ZBP1 recruits RIP1 and RIP3 through RIP homotypic interaction motifs to activate NF-kappaB. EMBO Rep. 2009;10(8): 916-922.
Crossref Google Scholar
19

Cusson-Hermance N, Khurana S, Lee TH, Fitzgerald KA, Kelliher MA. Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation. J Biol Chem. 2005;280(44): 36560-36566.
Crossref Google Scholar
20

Rickard JA, O'Donnell JA, Evans JM, et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell. 2014;157(5): 1175-1188.
Crossref Google Scholar
21

Pazdernik NJ, Donner DB, Goebl MG, Harrington MA. Mouse receptor interacting protein 3 does not contain a caspase-recruiting or a death domain but induces apoptosis and activates NF-kappaB. Mol Cell Biol. 1999;19(10): 6500-6508.
Crossref Google Scholar
22

Sun X, Lee J, Navas T, Baldwin DT, Stewart TA, Dixit VM. RIP3, a novel apoptosis-inducing kinase. J Biol Chem. 1999;274(24): 16871-16875.
Crossref Google Scholar
23

Yu PW, Huang BC, Shen M, et al. Identification of RIP3, a RIP-like kinase that activates apoptosis and NFkappaB. Curr Biol. 1999;9(10): 539-542.
Crossref Google Scholar
24

Kasof GM, Prosser JC, Liu D, Lorenzi MV, Gomes BC. The RIP-like kinase, RIP3, induces apoptosis and NF-kappaB nuclear translocation and localizes to mitochondria. FEBS Lett. 2000;473(3): 285-291.
Crossref Google Scholar
25

Khan N, Lawlor KE, Murphy JM, Vince JE. More to life than death: molecular determinants of necroptotic and non-necroptotic RIP3 kinase signaling. Curr Opin Immunol. 2014;26: 76-89.
Crossref Google Scholar
26

Mandal P, Berger SB, Pillay S, et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol Cell. 2014;56(4): 481-495.
Crossref Google Scholar
27

Moriwaki K, Bertin J, Gough PJ, Chan FK. A RIPK3-caspase 8 complex mediates atypical pro-IL-1β processing. J Immunol. 2015;194(4): 1938-1944.
Crossref Google Scholar
28

Newton K, Dugger DL, Wickliffe KE, et al. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science. 2014;343(6177): 1357-1360.
Crossref Google Scholar
29

Nogusa S, Thapa RJ, Dillon CP, et al. RIPK3 activates parallel pathways of MLKL-driven necroptosis and FADD-mediated apoptosis to protect against influenza A virus. Cell Host Microbe. 2016;20(1): 13-24.
Crossref Google Scholar
30

Li D, Chen J, Guo J, et al. A phosphorylation of RIPK3 kinase initiates an intracellular apoptotic pathway that promotes prostaglandin(2α)-induced corpus luteum regression. Elife. 2021;10: e67409.
Crossref Google Scholar
31

Kaiser WJ, Sridharan H, Huang C, et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem. 2013;288(43): 31268-31279.
Crossref Google Scholar
32

Upton JW, Kaiser WJ, Mocarski ES. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe. 2012;11(3): 290-297.
Crossref Google Scholar
33

Sarhan J, Liu BC, Muendlein HI, et al. Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis. Cell Death Differ. 2019;26(2): 332-347.
Crossref Google Scholar
34

Chen D, Tong J, Yang L, et al. PUMA amplifies necroptosis signaling by activating cytosolic DNA sensors. Proc Natl Acad Sci U S A. 2018;115(15): 3930-3935.
Crossref Google Scholar
35

He S, Liang Y, Shao F, Wang X. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc Natl Acad Sci U S A. 2011;108(50): 20054-20059.
Crossref Google Scholar
36

Cai Z, Liu ZG. Execution of RIPK3-regulated necrosis. Mol Cell Oncol. 2014;1(2): e960759.
Crossref Google Scholar
37

Dillon CP, Oberst A, Weinlich R, et al. Survival function of the FADD-CASPASE-8-cFLIP(L) complex. Cell Rep. 2012;1(5): 401-407.
Crossref Google Scholar
38

Chen D, Yu J, Zhang L. Necroptosis: an alternative cell death program defending against cancer. Biochim Biophys Acta. 2016;1865(2): 228-236.
Crossref Google Scholar
39

Bertrand MJ, Milutinovic S, Dickson KM, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell. 2008;30(6): 689-700.
Crossref Google Scholar
40

Zhang J, Webster JD, Dugger DL, et al. Ubiquitin ligases cIAP1 and cIAP2 limit cell death to prevent inflammation. Cell Rep. 2019;27(9): 2679-2689.
Crossref Google Scholar
41

Moquin DM, McQuade T, Chan FK. CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis. PLoS One. 2013;8(10): e76841.
Crossref Google Scholar
42

Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133(4): 693-703.
Crossref Google Scholar
43

Li J, McQuade T, Siemer AB, et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell. 2012;150(2): 339-350.
Crossref Google Scholar
44

Dhuriya YK, Sharma D. Necroptosis: a regulated inflammatory mode of cell death. J Neuroinflammation. 2018;15(1): 199.
Crossref Google Scholar
45

Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148(1–2): 213-227.
Crossref Google Scholar
46

Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013;38(2): 209-223.
Crossref Google Scholar
47

Inohara N, del Peso L, Koseki T, Chen S, Núñez G. RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis. J Biol Chem. 1998;273(20): 12296-12300.
Crossref Google Scholar
48

McCarthy JV, Ni J, Dixit VM. RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. J Biol Chem. 1998;273(27): 16968-16975.
Crossref Google Scholar
49

Sollberger G, Strittmatter GE, Garstkiewicz M, Sand J, Beer HD. Caspase-1: the inflammasome and beyond. Innate Immun. 2014;20(2): 115-125.
Crossref Google Scholar
50

Mukherjee T, Hovingh ES, Foerster EG, Abdel-Nour M, Philpott DJ, Girardin SE. NOD1 and NOD2 in inflammation, immunity and disease. Arch Biochem Biophys. 2019;670: 69-81.
Crossref Google Scholar
51

Gong Q, Long Z, Zhong FL, et al. Structural basis of RIP2 activation and signaling. Nat Commun. 2018;9(1): 4993.
Crossref Google Scholar
52

He S, Wang X. RIP kinases as modulators of inflammation and immunity. Nat Immunol. 2018;19(9): 912-922.
Crossref Google Scholar
53

Inohara N, Koseki T, Lin J, et al. An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. J Biol Chem. 2000;275(36): 27823-27831.
Crossref Google Scholar
54

Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem. 2001;276(7): 4812-4818.
Crossref Google Scholar
55

Chen L, Haider K, Ponda M, Cariappa A, Rowitch D, Pillai S. Protein kinase C-associated kinase (PKK), a novel membrane-associated, ankyrin repeat-containing protein kinase. J Biol Chem. 2001;276(24): 21737-21744.
Crossref Google Scholar
56

Bähr C, Rohwer A, Stempka L, Rincke G, Marks F, Gschwendt M. DIK, a novel protein kinase that interacts with protein kinase Cdelta. Cloning, characterization, and gene analysis. J Biol Chem. 2000;275(46): 36350-36357.
Crossref Google Scholar
57

Meylan E, Martinon F, Thome M, Gschwendt M, Tschopp J. RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF-kappa B and is processed during apoptosis. EMBO Rep. 2002;3(12): 1201-1208.
Crossref Google Scholar
58

Huang X, McGann JC, Liu BY, et al. Phosphorylation of Dishevelled by protein kinase RIPK4 regulates Wnt signaling. Science. 2013;339(6126): 1441-1445.
Crossref Google Scholar
59

Rountree RB, Willis CR, Dinh H, et al. RIP4 regulates epidermal differentiation and cutaneous inflammation. J Invest Dermatol. 2010;130(1): 102-112.
Crossref Google Scholar
60

Xu J, Wei Q, He Z. Insight into the function of RIPK4 in keratinocyte differentiation and carcinogenesis. Front Oncol. 2020;10: 1562.
Crossref Google Scholar
61

España-Serrano L, Guerra Martín-Palanco N, Montero-Pedrazuela A, et al. The addiction-related protein ANKK1 is differentially expressed during the cell cycle in neural precursors. Cereb Cortex. 2017;27(5): 2809-2819.
Crossref Google Scholar
62

Koeneke A, Ponce G, Troya-Balseca J, Palomo T, Hoenicka J. Ankyrin repeat and kinase domain containing 1 gene, and addiction vulnerability. Int J Mol Sci. 2020;21(7): 2516.
Crossref Google Scholar
63

Matsushima N, Takatsuka S, Miyashita H, Kretsinger RH. Leucine rich repeat proteins: sequences, mutations, structures and diseases. Protein Pept Lett. 2019;26(2): 108-131.
Crossref Google Scholar
64

Hanafusa H, Ishikawa K, Kedashiro S, et al. Leucine-rich repeat kinase LRRK1 regulates endosomal trafficking of the EGF receptor. Nat Commun. 2011;2: 158.
Crossref Google Scholar
65

Civiero L, Bubacco L. Human leucine-rich repeat kinase 1 and 2: intersecting or unrelated functions? Biochem Soc Trans. 2012;40(5): 1095-1101.
Crossref Google Scholar
66

Shin N, Jeong H, Kwon J, et al. LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res. 2008;314(10): 2055-2065.
Crossref Google Scholar
67

Kett LR, Dauer WT. Leucine-rich repeat kinase 2 for beginners: six key questions. Cold Spring Harb Perspect Med. 2012;2(3): a009407.
Crossref Google Scholar
68

Haugarvoll K, Toft M, Ross OA, White LR, Aasly JO, Farrer MJ. Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway. Neurosci Lett. 2007;416(3): 299-301.
Crossref Google Scholar
69

Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4): 601-607.
Crossref Google Scholar
70

Schulte EC, Ellwanger DC, Dihanich S, et al. Rare variants in LRRK1 and Parkinson's disease. Neurogenetics. 2014;15(1): 49-57.
Crossref Google Scholar
71

Berwick DC, Heaton GR, Azeggagh S, Harvey K. LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same. Mol Neurodegener. 2019;14(1): 49.
Crossref Google Scholar
72

Zhu G, Ye J, Huang Y, et al. Receptor-interacting protein-1 promotes the growth and invasion in gastric cancer. Int J Oncol. 2016;48(6): 2387-2398.
Crossref Google Scholar
73

McCormick KD, Ghosh A, Trivedi S, et al. Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma. Carcinogenesis. 2016;37(5): 522-529.
Crossref Google Scholar
74

Yin Z, Chen W, Yin J, et al. RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis. NPJ Breast Cancer. 2021;7(1): 53.
Crossref Google Scholar
75

Zhang Y, Du J, Duan X, et al. RIPK1 contributes to cisplatin-induced apoptosis of esophageal squamous cell carcinoma cells via activation of JNK pathway. Life Sci. 2021;269: 119064.
Crossref Google Scholar
76

Brown MF, Leibowitz BJ, Chen D, et al. Loss of caspase-3 sensitizes colon cancer cells to genotoxic stress via RIP1-dependent necrosis. Cell Death Dis. 2015;6(4): e1729.
Crossref Google Scholar
77

Park S, Hatanpaa KJ, Xie Y, et al. The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res. 2009;69(7): 2809-2816.
Crossref Google Scholar
78

Wang Q, Chen W, Xu X, et al. RIP1 potentiates BPDE-induced transformation in human bronchial epithelial cells through catalase-mediated suppression of excessive reactive oxygen species. Carcinogenesis. 2013;34(9): 2119-2128.
Crossref Google Scholar
79

Liu XY, Lai F, Yan XG, et al. RIP1 kinase is an oncogenic driver in melanoma. Cancer Res. 2015;75(8): 1736-1748.
Crossref Google Scholar
80

Zhu G, Chen X, Wang X, et al. Expression of the RIP-1 gene and its role in growth and invasion of human gallbladder carcinoma. Cell Physiol Biochem. 2014;34(4): 1152-1165.
Crossref Google Scholar
81

Seifert L, Werba G, Tiwari S, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature. 2016;532(7598): 245-249.
Crossref Google Scholar
82

Park S, Zhao D, Hatanpaa KJ, et al. RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB-mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and down-regulation of PTEN. Cancer Res. 2009;69(10): 4107-4111.
Crossref Google Scholar
83

Patel S, Webster JD, Varfolomeev E, et al. RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases. Cell Death Differ. 2020;27(1): 161-175.
Crossref Google Scholar
84

Zheng XL, Yang JJ, Wang YY, et al. RIP1 promotes proliferation through G2/M checkpoint progression and mediates cisplatin-induced apoptosis and necroptosis in human ovarian cancer cells. Acta Pharmacol Sin. 2020;41(9): 1223-1233.
Crossref Google Scholar
85

Wang X, Jiang W, Duan N, et al. NOD1, RIP2 and Caspase12 are potentially novel biomarkers for oral squamous cell carcinoma development and progression. Int J Clin Exp Pathol. 2014;7(4): 1677-1686.
Google Scholar
86

Zhang H, Chin AI. Role of Rip2 in development of tumor-infiltrating MDSCs and bladder cancer metastasis. PLoS One. 2014;9(4): e94793.
Crossref Google Scholar
87

Singel SM, Batten K, Cornelius C, et al. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways. Breast Cancer Res. 2014;16(2): R28.
Crossref Google Scholar
88

Jaafar RF, Ibrahim Z, Ataya K, Hassanieh J, Ard N, Faraj W. Receptor-interacting serine/threonine-protein kinase-2 as a potential prognostic factor in colorectal cancer. Medicina. 2021;57(7): 709.
Crossref Google Scholar
89

Li D, Tang L, Liu B, Xu S, Jin M, Bo W. RIPK2 is an unfavorable prognosis marker and a potential therapeutic target in human kidney renal clear cell carcinoma. Aging. 2021;13(7): 10450-10467.
Crossref Google Scholar
90

Chen Y, Chen Y, Zhang J, et al. Fusobacterium nucleatum promotes metastasis in colorectal cancer by activating autophagy signaling via the upregulation of CARD3 expression. Theranostics. 2020;10(1): 323-339.
Crossref Google Scholar
91

Yang Q, Tian S, Liu Z, Dong W. Knockdown of RIPK2 inhibits proliferation and migration, and induces apoptosis via the NF-κB signaling pathway in gastric cancer. Front Genet. 2021;12: 627464.
Crossref Google Scholar
92

Udden SMN, Peng L, Gan JL, et al. NOD2 suppresses colorectal tumorigenesis via downregulation of the TLR pathways. Cell Rep. 2017;19(13): 2756-2770.
Crossref Google Scholar
93

Couturier-Maillard A, Secher T, Rehman A, et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest. 2013;123(2): 700-711.
Crossref Google Scholar
94

Seifert L, Miller G. Molecular pathways: the necrosome-A target for cancer therapy. Clin Cancer Res. 2017;23(5): 1132-1136.
Crossref Google Scholar
95

Wang KJ, Wang KY, Zhang HZ, et al. Up-regulation of RIP3 alleviates prostate cancer progression by activation of RIP3/MLKL signaling pathway and induction of necroptosis. Front Oncol. 2020;10: 1720.
Crossref Google Scholar
96

Koo GB, Morgan MJ, Lee DG, et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 2015;25(6): 707-725.
Crossref Google Scholar
97

Moriwaki K, Bertin J, Gough PJ, Orlowski GM, Chan FK. Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. Cell Death Dis. 2015;6(2): e1636.
Crossref Google Scholar
98

Nugues AL, El Bouazzati H, Hétuin D, et al. RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage. Cell Death Dis. 2014;5(8): e1384.
Crossref Google Scholar
99

Tan Y, Sementino E, Cheung M, et al. Somatic epigenetic silencing of RIPK3 inactivates necroptosis and contributes to chemoresistance in malignant mesothelioma. Clin Cancer Res. 2021;27(4): 1200-1213.
Crossref Google Scholar
100

Wang Q, Wang P, Zhang L, et al. Epigenetic regulation of RIP3 suppresses necroptosis and increases resistance to chemotherapy in nonsmall cell lung cancer. Transl Oncol. 2020;13(2): 372-382.
Crossref Google Scholar
101

Won KY, Min SY, Song JY, Lim SJ, Han SA. Clinical significance of receptor-interacting protein 3 and Parkin, essential molecules for necroptosis, in breast cancer. J Breast Cancer. 2021;24(1): 34-48.
Crossref Google Scholar
102

Conev NV, Dimitrova EG, Bogdanova MK, et al. RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer. Clin Invest Med. 2019;42(1): E31-E38.
Crossref Google Scholar
103

Geserick P, Wang J, Schilling R, et al. Absence of RIPK3 predicts necroptosis resistance in malignant melanoma. Cell Death Dis. 2015;6(9): e1884.
Crossref Google Scholar
104

Feng X, Song Q, Yu A, Tang H, Peng Z, Wang X. Receptor-interacting protein kinase 3 is a predictor of survival and plays a tumor suppressive role in colorectal cancer. Neoplasma. 2015;62(4): 592-601.
Crossref Google Scholar
105

Cerhan JR, Ansell SM, Fredericksen ZS, et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood. 2007;110(13): 4455-4463.
Crossref Google Scholar
106

Meng MB, Wang HH, Cui YL, et al. Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy. Oncotarget. 2016;7(35): 57391-57413.
Crossref Google Scholar
107

Mutirangura A, Pornthanakasem W, Sriuranpong V, Supiyaphun P, Voravud N. Loss of heterozygosity on chromosome 14 in nasopharyngeal carcinoma. Int J Cancer. 1998;78(2): 153-156.
Crossref Google Scholar
108

Kopparam J, Chiffelle J, Angelino P, et al. RIP4 inhibits STAT3 signaling to sustain lung adenocarcinoma differentiation. Cell Death Differ. 2017;24(10): 1761-1771.
Crossref Google Scholar
109

Wang X, Zhu W, Zhou Y, Xu W, Wang H. RIPK4 is downregulated in poorly differentiated tongue cancer and is associated with migration/invasion and cisplatin-induced apoptosis. Int J Biol Markers. 2014;29(2): e150-e159.
Crossref Google Scholar
110

Heim D, Cornils K, Schulze K, et al. Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis. Oncogene. 2015;34(3): 364-372.
Crossref Google Scholar
111

Ge Y, He Z, Xiang Y, et al. The identification of key genes in nasopharyngeal carcinoma by bioinformatics analysis of high-throughput data. Mol Biol Rep. 2019;46(3): 2829-2840.
Crossref Google Scholar
112

Gong Y, Luo X, Yang J, Jiang Q, Liu Z. RIPK4 promoted the tumorigenicity of nasopharyngeal carcinoma cells. Biomed Pharmacother. 2018;108: 1-6.
Crossref Google Scholar
113

Azizmohammadi S, Azizmohammadi S, Safari A, et al. High-level expression of RIPK4 and EZH2 contributes to lymph node metastasis and predicts favorable prognosis in patients with cervical cancer. Oncol Res. 2017;25(4): 495-501.
Crossref Google Scholar
114

Liu JY, Zeng QH, Cao PG, et al. RIPK4 promotes bladder urothelial carcinoma cell aggressiveness by upregulating VEGF-A through the NF-κB pathway. Br J Cancer. 2018;118(12): 1617-1627.
Crossref Google Scholar
115

Qi ZH, Xu HX, Zhang SR, et al. RIPK4/PEBP1 axis promotes pancreatic cancer cell migration and invasion by activating RAF1/MEK/ERK signaling. Int J Oncol. 2018;52(4): 1105-1116.
Crossref Google Scholar
116

Yi H, Su YZ, Lin R, et al. Downregulation of RIPK4 expression inhibits epithelial-mesenchymal transition in ovarian cancer through IL-6. J Immunol Res. 2021;2021: 8875450.
Crossref Google Scholar
117

Liu DQ, Li FF, Zhang JB, et al. Increased RIPK4 expression is associated with progression and poor prognosis in cervical squamous cell carcinoma patients. Sci Rep. 2015;5: 11955.
Crossref Google Scholar
118

Kim SW, Oleksyn DW, Rossi RM, et al. Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells. Blood. 2008;111(3): 1644-1653.
Crossref Google Scholar
119

Yi Z, Pu Y, Gou R, et al. Silencing of RIPK4 inhibits epithelial-mesenchymal transition by inactivating the Wnt/β-catenin signaling pathway in osteosarcoma. Mol Med Rep. 2020;21(3): 1154-1162.
Crossref Google Scholar
120

Zhong F, Wu Q, Xia G, Liu L, Yu T. RIP6 suppresses tumor cell growth in hepatocellular carcinoma. Clin Lab. 2020;66(9): 1851-1858.
Crossref Google Scholar
121

Fukasawa M, Kimura M, Morita S, et al. Microarray analysis of promoter methylation in lung cancers. J Hum Genet. 2006;51(4): 368-374.
Crossref Google Scholar
122

Jung G, Hernández-Illán E, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;17(2): 111-130.
Crossref Google Scholar
123

Yang C, Li J, Yu L, et al. Regulation of RIP3 by the transcription factor Sp1 and the epigenetic regulator UHRF1 modulates cancer cell necroptosis. Cell Death Dis. 2017;8(10): e3084.
Crossref Google Scholar
124

Hänggi K, Vasilikos L, Valls AF, et al. RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function. Cell Death Dis. 2017;8(2): e2588.
Crossref Google Scholar
125

Li Y, Xiong Y, Zhang G, et al. Identification of 5-(2, 3-dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2, 3- d]pyrimidin-4-amine derivatives as a new class of receptor-interacting protein kinase 1 (RIPK1) inhibitors, which showed potent activity in a tumor metastasis model. J Med Chem. 2018;61(24): 11398-11414.
Crossref Google Scholar
126

Strilic B, Yang L, Albarrán-Juárez J, et al. Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis. Nature. 2016;536(7615): 215-218.
Crossref Google Scholar
127

Zhu F, Zhang W, Yang T, He SD. Complex roles of necroptosis in cancer. J Zhejiang Univ Sci B. 2019;20(5): 399-413.
Crossref Google Scholar
128

Kang AR, Cho JH, Lee NG, et al. RIP1 is a novel component of γ-ionizing radiation-induced invasion of non-small cell lung cancer cells. Int J Mol Sci. 2020;21(13): 4584.
Crossref Google Scholar
129

Zhu G, Du Q, Chen X, et al. Receptor-interacting serine/threonine-protein kinase 1 promotes the progress and lymph metastasis of gallbladder cancer. Oncol Rep. 2019;42(6): 2435-2449.
Crossref Google Scholar
130

Li CZ, Jiang XJ, Lin B, et al. RIP1 regulates TNF-α-mediated lymphangiogenesis and lymphatic metastasis in gallbladder cancer by modulating the NF-κB-VEGF-C pathway. Onco Targets Ther. 2018;11: 2875-2890.
Crossref Google Scholar
131

Liu X, Zhou M, Mei L, et al. Key roles of necroptotic factors in promoting tumor growth. Oncotarget. 2016;7(16): 22219-22233.
Crossref Google Scholar
132

Vucur M, Reisinger F, Gautheron J, et al. RIP3 inhibits inflammatory hepatocarcinogenesis but promotes cholestasis by controlling caspase-8- and JNK-dependent compensatory cell proliferation. Cell Rep. 2013;4(4): 776-790.
Crossref Google Scholar
133

Höckendorf U, Yabal M, Herold T, et al. RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells. Cancer Cell. 2016;30(1): 75-91.
Crossref Google Scholar
134

Ruan H, Leibowitz BJ, Zhang L, Yu J. Immunogenic cell death in colon cancer prevention and therapy. Mol Carcinog. 2020;59(7): 783-793.
Crossref Google Scholar
135

Yan G, Zhao H, Zhang Q, et al. A RIPK3-PGE(2) circuit mediates myeloid-derived suppressor cell-potentiated colorectal carcinogenesis. Cancer Res. 2018;78(19): 5586-5599.
Crossref Google Scholar
136

Jing L, Zhai ME, Cui J, et al. CNOT3 contributes to cisplatin resistance in lung cancer through inhibiting RIPK3 expression. Apoptosis. 2019;24(7–8): 673-685.
Crossref Google Scholar
137

Yang H, Ma Y, Chen G, et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology. 2016;5(6): e1149673.
Crossref Google Scholar
138

Oliver Metzig M, Fuchs D, Tagscherer KE, Gröne HJ, Schirmacher P, Roth W. Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-α-dependent necroptosis driven by RIP1 kinase and NF-κB. Oncogene. 2016;35(26): 3399-3409.
Crossref Google Scholar
139

Tenev T, Bianchi K, Darding M, et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell. 2011;43(3): 432-448.
Crossref Google Scholar
140

Su Z, Yang Z, Xie L, DeWitt JP, Chen Y. Cancer therapy in the necroptosis era. Cell Death Differ. 2016;23(5): 748-756.
Crossref Google Scholar
141

Pietkiewicz S, Eils R, Krammer PH, Giese N, Lavrik IN. Combinatorial treatment of CD95L and gemcitabine in pancreatic cancer cells induces apoptotic and RIP1-mediated necroptotic cell death network. Exp Cell Res. 2015;339(1): 1-9.
Crossref Google Scholar
142

Wang Y, Zheng Y, Hao Y. Rucaparip (Rubraca(®)) induces necrosis via upregulating the expression of RIP1 and RIP3 in ovarian cancer cells. Pharmazie. 2020;75(6): 242-245.
Crossref Google Scholar
143

Zhang Z, Ju F, Chen F, et al. GDC-0326 enhances the effects of 5-Fu in colorectal cancer cells by inducing necroptotic death. Onco Targets Ther. 2021;14: 2519-2530.
Crossref Google Scholar
144

Dunai ZA, Imre G, Barna G, et al. Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells. PLoS One. 2012;7(7): e41945.
Crossref Google Scholar
145

Han W, Li L, Qiu S, et al. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther. 2007;6(5): 1641-1649.
Crossref Google Scholar
146

Yu X, Deng Q, Li W, et al. Neoalbaconol induces cell death through necroptosis by regulating RIPK-dependent autocrine TNFα and ROS production. Oncotarget. 2015;6(4): 1995-2008.
Crossref Google Scholar
147

Gong Y, Fan Z, Luo G, et al. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18(1): 100.
Crossref Google Scholar
148

Sun W, Yu J, Gao H, et al. Inhibition of lung cancer by 2-methoxy-6-acetyl-7-methyljuglone through induction of necroptosis by targeting receptor-interacting protein 1. Antioxid Redox Signal. 2019;31(2): 93-108.
Crossref Google Scholar
149

Liu T, Sun X, Cao Z. Shikonin-induced necroptosis in nasopharyngeal carcinoma cells via ROS overproduction and upregulation of RIPK1/RIPK3/MLKL expression. Onco Targets Ther. 2019;12: 2605-2614.
Crossref Google Scholar
150

Zhao X, Quan J, Tan Y, et al. RIP3 mediates TCN-induced necroptosis through activating mitochondrial metabolism and ROS production in chemotherapy-resistant cancers. Am J Cancer Res. 2021;11(3): 729-745.
Crossref Google Scholar
151

Chen C, Xiao W, Huang L, et al. Shikonin induces apoptosis and necroptosis in pancreatic cancer via regulating the expression of RIP1/RIP3 and synergizes the activity of gemcitabine. Am J Transl Res. 2017;9(12): 5507-5517.
Google Scholar
152

Xuan Y, Hu X. Naturally-occurring shikonin analogues--a class of necroptotic inducers that circumvent cancer drug resistance. Cancer Lett. 2009;274(2): 233-242.
Crossref Google Scholar
153

Whilding LM, Archibald KM, Kulbe H, Balkwill FR, Öberg D, McNeish IA. Vaccinia virus induces programmed necrosis in ovarian cancer cells. Mol Ther. 2013;21(11): 2074-2086.
Crossref Google Scholar
154

Wu Y, Dong G, Sheng C. Targeting necroptosis in anticancer therapy: mechanisms and modulators. Acta Pharm Sin B. 2020;10(9): 1601-1618.
Crossref Google Scholar
155

Harris PA, Marinis JM, Lich JD, et al. Identification of a RIP1 kinase inhibitor clinical candidate (GSK3145095) for the treatment of pancreatic cancer. ACS Med Chem Lett. 2019;10(6): 857-862.
Crossref Google Scholar
156

Hou J, Ju J, Zhang Z, et al. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis. Cell Death Dis. 2019;10(7): 493.
Crossref Google Scholar
157

Li JX, Feng JM, Wang Y, et al. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis. 2014;5(6): e1278.
Crossref Google Scholar
158

Yatim N, Jusforgues-Saklani H, Orozco S, et al. RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8⁺ T cells. Science. 2015;350(6258): 328-334.
Crossref Google Scholar
159

Smith HG, Jamal K, Dayal JH, et al. RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma. EMBO Mol Med. 2020;12(6): e10979.
Crossref Google Scholar
160

Kang YJ, Bang BR, Han KH, et al. Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling. Nat Commun. 2015;6: 8371.
Crossref Google Scholar
161

Snyder AG, Hubbard NW, Messmer MN, et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci Immunol. 2019;4(36): eaaw2004.
Crossref Google Scholar
162

Wang W, Marinis JM, Beal AM, et al. RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer. Cancer Cell. 2018;34(5): 757-774.
Crossref Google Scholar
163

Jayakumar A, Bothwell ALM. RIPK3-induced inflammation by I-MDSCs promotes intestinal tumors. Cancer Res. 2019;79(7): 1587-1599.
Crossref Google Scholar
Genes & Diseases
Volume 9 Issue 6,
November 2022
Pages 1579-1593
DOI: 10.1016/j.gendis.2021.10.007
Cite this article:
Ermine K, Yu J, Zhang L. Role of Receptor Interacting Protein (RIP) kinases in cancer. Genes & Diseases, 2022, 9(6): 1579-1593. https://doi.org/10.1016/j.gendis.2021.10.007

344

Views

3

Downloads

18

Crossref

16

Web of Science

16

Scopus

0

CSCD

Altmetrics
Received: 16 September 2021
Revised: 18 October 2021
Accepted: 26 October 2021
Published: 18 November 2021
© 2021, Chongqing Medical University.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return